Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AS Latvijas Juras medicinas centrs's enterprise value is €5.09 Mil.
AS Latvijas Juras medicinas centrs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €0.43 Mil. Therefore, AS Latvijas Juras medicinas centrs's EV-to-EBITDA for today is 11.97.
ORSE:LJM1R'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -221.96 Med: 11.06 Max: 205.36
Current: 11.97
During the past 13 years, the highest EV-to-EBITDA of AS Latvijas Juras medicinas centrs was 205.36. The lowest was -221.96. And the median was 11.06.
ORSE:LJM1R's EV-to-EBITDA is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 10.62
vs ORSE:LJM1R: 11.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AS Latvijas Juras medicinas centrs's PE Ratio (TTM) for today is calculated as:
AS Latvijas Juras medicinas centrs's share price for today is €7.80.
AS Latvijas Juras medicinas centrs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.299.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AS Latvijas Juras medicinas centrs EV-to-EBITDA Chart
ORSE:LJM1R vs HCA, THC, ENSG: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, AS Latvijas Juras medicinas centrs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AS Latvijas Juras medicinas centrs EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, AS Latvijas Juras medicinas centrs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AS Latvijas Juras medicinas centrs's EV-to-EBITDA falls into.
AS Latvijas Juras medicinas centrs's current Enterprise Value is €5.09 Mil.
AS Latvijas Juras medicinas centrs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a EV-to-EBITDA of 11.97 as of Aug. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AS Latvijas Juras medicinas centrs. This is near median its historical median of 11.06.
Is AS Latvijas Juras medicinas centrs' EV-to-EBITDA too high?
AS Latvijas Juras medicinas centrs' current EV-to-EBITDA of 11.97 is near median its 10-year median of 11.06. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.62. AS Latvijas Juras medicinas centrs' value of 11.97 is 12.7% above this industry median. Overall, AS Latvijas Juras medicinas centrs has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does AS Latvijas Juras medicinas centrs' EV-to-EBITDA compare to HCA and THC?
AS Latvijas Juras medicinas centrs' EV-to-EBITDA of 11.97 can be compared against companies in the Healthcare Providers & Services industry. The industry median EV-to-EBITDA is 10.62. AS Latvijas Juras medicinas centrs' value of 11.97 is 12.7% above this benchmark. While the company's 10-year median is 11.06 vs. the industry median of 10.62, AS Latvijas Juras medicinas centrs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.62, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AS Latvijas Juras medicinas centrs's current EV-to-EBITDA of 11.97 is 12.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AS Latvijas Juras medicinas centrs. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AS Latvijas Juras medicinas centrs's current EV-to-EBITDA is 11.97, which is near median its own 10-year median of 11.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AS Latvijas Juras medicinas centrs stock overvalued right now?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a current EV-to-EBITDA of 11.97. The stock's GF Value™ is €7.78, compared to a current price of €7.80 — trading 0.3% above its estimated fair value. The current EV-to-EBITDA is 11.97, which is near median its 10-year median of 11.06 and 12.7% above the Healthcare Providers & Services industry median of 10.62. AS Latvijas Juras medicinas centrs' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AS Latvijas Juras medicinas centrs (ORSE:LJM1R), the current EV-to-EBITDA is 11.97 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Overvalued in 2026?
Based on GuruFocus' analysis, AS Latvijas Juras medicinas centrs stock appears to be overvalued.
The current stock price of €7.80 is trading 0.3% above its estimated GF Value™ of €7.78.
Key valuation signals for ORSE:LJM1R:
EV-to-EBITDA: 11.97 (near median its 10-year median of 11.06)
GF Value™: €7.78 vs. price of €7.80 (0.3% above fair value)
Industry Position: 12.7% above the Healthcare Providers & Services median
No single metric tells the full story. See the ORSE:LJM1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AS Latvijas Juras medicinas centrs is a private certified medical institution in Latvia providing outpatient and inpatient healthcare services through qualified staff and modern equipment. Its core activities include hospital services, orthopaedic retail, medical and dental practice, human health and residential care, social work activities, and physical well-being services. It operates the Women's Health Clinic, offering gynecological consultations, pregnancy care, diagnostics, postpartum services, gynecological care for girls, and surgery. The centre also provides vaccination, rehabilitation, a Multiple Sclerosis Center, medical commission, home visits, laboratory services, physical medicine and massage, therapeutic procedures, medical treatment, and anesthesia and intensive care.
59GF Score
Get the complete analysis for ORSE:LJM1R
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORSE:LJM1R has been successfully added to your 
